Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab Combined With Gemcitabine and Oxaliplatin in Relapsed/Refractory PCNSL and SCNSL
NCT07888621Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab in primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective Response Rate at 18 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
glofitamab
03
Conditions
primary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NCT07888621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07888621.